Bioinformatics Analysis Reveals the Potential Target of Rosiglitazone As an Antiangiogenic Agent for Breast Cancer Therapy

Overview

Journal BMC Genom Data

Publisher Biomed Central

Specialty Genetics

Date 2022 Sep 16

PMID 36114448

Authors

Adam Hermawan

Herwandhani Putri

Affiliations

Soon will be listed here.

Abstract

Background: Several studies have demonstrated the antitumor activity of rosiglitazone (RGZ) in cancer cells, including breast cancer cells. However, the molecular targets of RGZ in the inhibition of angiogenesis in breast cancer cells remain unclear. This study aimed to explore the potential targets of RGZ in inhibiting breast cancer angiogenesis using bioinformatics-based analysis.

Results: Venn diagram analysis revealed 29 TR proteins. KEGG pathway enrichment analysis demonstrated that TR regulated the adipocytokine, AMPK, and PPAR signaling pathways. Oncoprint analysis showed genetic alterations in FABP4 (14%), ADIPOQ (2.9%), PPARG (2.8%), PPARGC1A (1.5%), CD36 (1.7%), and CREBBP (11%) in patients with breast cancer in a TCGA study. The mRNA levels of FABP4, ADIPOQ, PPARG, CD36, and PPARGC1A were significantly lower in patients with breast cancer than in those without breast cancer. Analysis of gene expression using bc-GenExMiner showed that the mRNA levels of FABP, ADIPOQ, PPARG, CD36, PPARGC1A, and CREBBP were significantly lower in basal-like and triple-negative breast cancer (TNBC) cells than in non-basal-like and non-TNBC cells. In general, the protein levels of these genes were low, except for that of CREBBP. Patients with breast cancer who had low mRNA levels of FABP4, ADIPOQ, PPARG, and PPARGC1A had lower overall survival rates than those with high mRNA levels, which was supported by the overall survival related to DNA methylation. Correlation analysis of immune cell infiltration with TR showed a correlation between TR and immune cell infiltration, highlighting the potential of RGZ for immunotherapy.

Conclusion: This study explored the potential targets of RGZ as antiangiogenic agents in breast cancer therapy and highlighted FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP as potential targets of RGZ. These findings require further validation to explore the potential of RGZ as an antiangiogenic agent.

Citing Articles

Transcriptomics analysis reveals distinct mechanism of breast cancer stem cells regulation in mammospheres from MCF-7 and T47D cells.

Hermawan A, Putri H, Fatimah N, Prasetio H Heliyon. 2024; 10(2):e24356.

PMID: 38304813 PMC: 10831612. DOI: 10.1016/j.heliyon.2024.e24356.

References

Li Y, Melnikov A, Levenson V, Guerra E, Simeone P, Alberti S . A seven-gene CpG-island methylation panel predicts breast cancer progression. BMC Cancer. 2015; 15:417. PMC: 4438505. DOI: 10.1186/s12885-015-1412-9. View

Mody M, Dharker N, Bloomston M, Wang P, Chou F, Glickman T . Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocr Relat Cancer. 2007; 14(2):305-15. DOI: 10.1677/ERC-06-0003. View

Rui M, Huang Z, Liu Y, Wang Z, Liu R, Fu J . Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia-inducible factor-1α and insulin-like growth factor-1 mRNA expression. Mol Med Rep. 2014; 10(4):2137-43. DOI: 10.3892/mmr.2014.2407. View

Comunanza V, Bussolino F . Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Front Cell Dev Biol. 2017; 5:101. PMC: 5725406. DOI: 10.3389/fcell.2017.00101. View

Szklarczyk D, Santos A, von Mering C, Jensen L, Bork P, Kuhn M . STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2015; 44(D1):D380-4. PMC: 4702904. DOI: 10.1093/nar/gkv1277. View

Yang S, Gong Z, Liu Z, Wei M, Xue L, Vlantis A . Differential Effects of Estrogen Receptor Alpha and Beta on Endogenous Ligands of Peroxisome Proliferator-Activated Receptor Gamma in Papillary Thyroid Cancer. Front Endocrinol (Lausanne). 2021; 12:708248. PMC: 8453163. DOI: 10.3389/fendo.2021.708248. View

Vergara D, Stanca E, Guerra F, Priore P, Gaballo A, Franck J . β-Catenin Knockdown Affects Mitochondrial Biogenesis and Lipid Metabolism in Breast Cancer Cells. Front Physiol. 2017; 8:544. PMC: 5529387. DOI: 10.3389/fphys.2017.00544. View

Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J . MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2017; 10(3):277-288. DOI: 10.2217/epi-2017-0118. View

Esfahani M, Movahedian A, Baranchi M, Goodarzi M . Adiponectin: an adipokine with protective features against metabolic syndrome. Iran J Basic Med Sci. 2015; 18(5):430-42. PMC: 4475650. View

10.

Kiely M, Tse L, Koka H, Wang D, Lee P, Wang F . Age-related DNA methylation in paired normal and tumour breast tissue in Chinese breast cancer patients. Epigenetics. 2020; 16(6):677-691. PMC: 8143246. DOI: 10.1080/15592294.2020.1819661. View

11.

Chu R, van Hasselt A, Vlantis A, Ng E, Liu S, Fan M . The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer. Cancer. 2013; 120(1):142-53. DOI: 10.1002/cncr.28383. View

12.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

13.

Mahmoud E, Fawzy A, El-Din W, Shafik N . Diagnostic value of adiponectin gene polymorphism and serum level in postmenopausal obese patients with breast cancer. J Cancer Res Ther. 2020; 16(6):1269-1273. DOI: 10.4103/jcrt.JCRT_1091_19. View

14.

Anuraga G, Wang W, Phan N, An Ton N, Ta H, Prayugo F . Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer. J Pers Med. 2021; 11(11). PMC: 8625415. DOI: 10.3390/jpm11111089. View

15.

Xiang X, Saha A, Wen R, Ruderman N, Luo Z . AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 2004; 321(1):161-7. DOI: 10.1016/j.bbrc.2004.06.133. View

16.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

17.

Chin C, Chen S, Wu H, Ho C, Ko M, Lin C . cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014; 8 Suppl 4:S11. PMC: 4290687. DOI: 10.1186/1752-0509-8-S4-S11. View

18.

Rajabi M, Mousa S . The Role of Angiogenesis in Cancer Treatment. Biomedicines. 2017; 5(2). PMC: 5489820. DOI: 10.3390/biomedicines5020034. View

19.

Zhao H, Kan Y, Wang X, Chen L, Ge P, Qian Z . Genetic polymorphism and transcriptional regulation of gene in patient with diffuse large B-cell lymphoma. Biosci Rep. 2019; 39(8). PMC: 6692565. DOI: 10.1042/BSR20191162. View

20.

Jezequel P, Gouraud W, Ben Azzouz F, Guerin-Charbonnel C, Juin P, Lasla H . bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses. Database (Oxford). 2021; 2021. PMC: 7904047. DOI: 10.1093/database/baab007. View